We are leveraging our insights into targeting IDPs to address the oncogenes most important for cancer patients. Our most advanced program is our first-in-class direct, orally bioavailable, small molecule MYC inhibitor, VOR-001. Our IDP platform is also being applied to other critical IDPs.
Series of analogues that have distinct mechanism of action
Orally bioavailable MYC inhibitor
Developed for patient selection